Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Non-Current Liabilities data on file, last reported at $316.1 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $316.1 million, down 6.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $316.1 million (down 6.34% YoY), and the FY2025 annual result was $242.6 million, down 33.5% from the prior year.
• Total Non-Current Liabilities improved to $316.1 million in Q1 2026 per BEAM's latest filing, from $242.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $635.5 million in Q3 2022 and troughed at $242.6 million in Q4 2025.
• A 5-year average of $454.0 million and a median of $443.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 153.6% in 2022, then sank 33.5% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $606.9 million in 2022, then retreated by 21.62% to $475.7 million in 2023, then declined by 23.29% to $364.9 million in 2024, then slumped by 33.5% to $242.6 million in 2025, then soared by 30.25% to $316.1 million in 2026.
• Business Quant data shows BEAM's Total Non-Current Liabilities at $316.1 million in Q1 2026, $242.6 million in Q4 2025, and $344.8 million in Q3 2025.